Montelukast Sandoz 4mg Chewable Tablets
Out of date information, search anotherRead all of this leaflet carefully before your child starts taking this
medicine.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, please ask your doctor or pharmacist.
• This medicine has been prescribed for your child. Do not pass it on to others. It may harm them, even if their symptoms are the same as your child’s.
• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
1. What Montelukast is and what it is used for
2. Before Montelukast is taken
3. How to take Montelukast
4. Possible side effects
5. How to store Montelukast
6. Further information
Montelukast is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Montelukast improves asthma symptoms and helps control asthma.
Your doctor has prescribed Montelukast to treat your child’s asthma, preventing asthma symptoms during the day and night.
• Montelukast 4 mg is used for the treatment of 2 to 5 year old patients who are not adequately controlled on their medication and need additional therapy.
• Montelukast 4 mg may also be used as an alternative treatment to inhaled corticosteroids for 2 to
5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.
• Montelukast 4 mg also helps prevent the narrowing of airways triggered by exercise for patients 2 years of age and older.
Taking other medicines
Some medicines may affect how Montelukast works, or Montelukast may affect how your child’s other medicines work.
Please tell your doctor or pharmacist if your child is taking or has recently taken other medicines, including those obtained without a prescription.
Tell your doctor if your child is taking the following medicines before starting Montelukast:
• phenobarbital (used for treatment of epilepsy)
• phenytoin (used for treatment of epilepsy)
• rifampicin (used to treat tuberculosis and some other infections)
Taking Montelukast with food and drink
Montelukast should not be taken immediately with food; they should be taken at least 1 hour before or 2 hours after food.
Pregnancy and breast-feeding
This subsection is not applicable for Montelukast 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.
Your doctor will determine how
Montelukast should be used
depending on the symptoms and
severity of your child's asthma.
What is asthma?
Asthma is a long-term disease.
Asthma includes:
• difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.
• sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.
• swelling (inflammation) in the lining of the airways.
Symptoms of asthma include: Coughing, wheezing, and chest tightness.
Tell your doctor about any medical
problems or allergies your child has
now or has had.
Do not give Montelukast to your
child if he/she
• is allergic (hypersensitive) to montelukast or any of the other ingredients of Montelukast 4 mg chewable tablets (see 6. Further information).
Take special care with Montelukast
• If your child’s asthma or breathing gets worse, tell your doctor immediately.
• Oral Montelukast is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you for your child. Always have your child’s inhaled rescue medicine for asthma attacks with you.
• It is important that your child takes all asthma medications prescribed by your doctor.
Montelukast should not be used instead of other asthma medications your doctor has prescribed for your child.
• If your child is on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.
• Your child should not take aspirin (acetyl-salicylic acid) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.
Use in pregnancy
Women who are pregnant or intend to become pregnant should consult their doctor before taking Montelukast. Your doctor will assess whether you can take Montelukast during this time.
Use in breast-feeding It is not known if montelukast appears in breast milk. You should consult your doctor before taking Montelukast if you are breast-feeding or intend to breast-feed.
Driving and using machines
This subsection is not applicable for Montelukast 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.
Montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with montelukast may affect some patients’ ability to drive or operate machinery.
Important information about some of the ingredients of Montelukast
Montelukast chewable tablets contain aspartame, which contains a source of phenylalanine. This may be harmful for people with phenylketonuria (a rare, hereditary disorder of the metabolism).
Montelukast 4 mg chewable tablets contain phenylalanine (equivalent to 0.539 mg phenylalanine per 4 mg chewable tablet).
Montelukast 4 mg chewable tablets contain Allura Red (E129). This may cause allergic reactions.
• This medicine is to be given to a child under adult supervision.
• Your child should take only one tablet of Montelukast once a day as prescribed by your doctor.
• It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.
• Always have your child take Montelukast as your doctor has told you. You should check with your child’s doctor or pharmacist if you are not sure.
• To be taken by mouth.
For children 2 to 5 years of age:
One 4 mg chewable tablet daily to be taken in the evening. Montelukast should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.
If your child is taking Montelukast, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.
Montelukast is not recommended below 2 years of age.
Different strengths and dosage forms may be available for the other age groups:
• 5 mg chewable tablets are available for children 6 to 14 years of age.
• 10 mg tablets are available for adults and adolescents 15 years of age and older.
If your child takes more Montelukast than he/she should
Contact your child’s doctor immediately for advice.
There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.
If you forget to give Montelukast to your child
Try to give Montelukast as prescribed.
However, if your child misses a dose, just resume the usual schedule of one tablet once daily.
Do not give a double dose to make up for a forgotten dose.
If your child stops taking Montelukast
Montelukast can treat your child’s asthma only if he/she continues taking it.
It is important for your child to continue taking Montelukast for as long as your doctor prescribes. It will help control your child’s asthma.
If you have any further questions on the use of this product, ask your child’s doctor or pharmacist.
commonly on your shins (erythema nodosum)
• joint or muscle pain, muscle cramps
• tiredness, feeling unwell, swelling, fever.
In asthmatic patients treated with montelukast, very rare cases (affects less than 1 user in 10,000) of a combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been reported. You must tell your doctor right away if your child gets one or more of these symptoms.
Ask your doctor or pharmacist for more information about side effects. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your child’s doctor or pharmacist.
Keep out of the reach and sight of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture and light. Medicines should not be disposed of via
wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Like all medicines, Montelukast can cause side effects, although not everybody gets them.
Serious side effects If you develop any of the following side effects, contact your doctor immediately:
• a combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been reported. You must tell your doctor right away if your child gets one or more of these symptoms
• allergic reactions including rash, swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing
• behaviour and mood related changes (dream abnormalities, including nightmares, trouble sleeping, sleepwalking, irritability, feeling anxious, restlessness, agitation including aggressive behaviour or hostility, depression).
In clinical studies with 4 mg chewable tablets, the most commonly reported side effects (affects 1 to 10 users in 100) thought to be related to montelukast were:
• abdominal pain
• thirst.
These were usually mild and occurred at a greater frequency in patients treated with montelukast than placebo (a pill containing no medication).
Additionally, while the medicine has been on the market, the following have been reported:
• increased bleeding tendency
• allergic reactions including rash, swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing
• behaviour and mood related changes [dream abnormalities including nightmares, hallucinations, irritability, feeling anxious, restlessness, agitation including aggressive behaviour, tremor, depression, trouble sleeping, suicidal thoughts and actions (in very rare cases)]
• dizziness, drowsiness, pins and needles/numbness, seizure
• palpitations
• nosebleed
• diarrhoea, dry mouth, indigestion, nausea, vomiting
• hepatitis
• bruising, itching, hives, tender red lumps under the skin most
• The active substance is montelukast.
Each tablet contains 4 mg of montelukast as montelukast sodium.
• The other ingredients are:
Mannitol (E421), cellulose microcrystalline,
hydroxypropylcellulose (E463), iron oxide, red (E172), croscarmellose sodium, flavour (Cherry Flavour AP0551, Cherry Duarome TD0990B [contains Allura Red, E129]), aspartame (E951) and magnesium stearate.
What Montelukast looks like and contents of the pack
4 mg Montelukast chewable tablets are pink to slightly speckled pink, oval with ‘4’ encoded on one side.
Montelukast is available in packs of:
7, 10, 14, 15, 20, 28, 30, 49, 50, 56, 60, 84, 90, 98, 100, 140, 200 chewable tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Sandoz Ltd,
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR,
United Kingdom.
Manufacturer
Salutas Pharma GmbH, Otto-von-Guericke-Allee 1,39179 Barleben, Germany
or
Salutas Pharma GmbH,
Dieselstrasse 5, 70839 Gerlingen, Germany
or
Lek Pharmaceuticals d.d.,
Verovskova 57, 1526 Ljubljana, Slovenia
or
Lek Pharmaceuticals d.d., Trimlini 2 D, 9220 Lendava, Slovenia
or
LEK S.A., Ul. Podlipie 16 C, 95 010 Strykow, Poland
or
LEK S.A., Ul. Domaniewska 50, 02672 Warszawa, Poland
or
S.C. Sandoz S.R.L., Str. Livezeni nr. 7A, 540472 Targu-Mures, Romania
This leaflet was last revised in 03/2015.
00000000
SZ00000LT000